6446.TW PHARMAESSENTIA CORP | TW0006446008
Company Profile
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Latest News
3Shape's TRIOS MOVE Pro Scanner Cart Wins Red Dot 2026 Design Award
PR Newswire • 07/27/2026
AI Usage Among 7th Gen Galaxy Foldables Users Grows in Southeast Asia and Oceania as Mobile Continues to be the Primary Gateway to AI
PR Newswire • 07/27/2026
Take Five: A crude summer
Reuters • 07/27/2026
Bank of England to keep rate steady despite oil and gas price rebound
Reuters • 07/27/2026
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Website | https://www.pharmaessentia.com |
| Audit Risk | 3 |
| Board Risk | 9 |
| Overall Risk | 6 |
| Market Cap | 493.67B |
| Trailing P/E | 82.93 |
| Forward P/E | 37.18 |
| Dividend Rate | 1.49 |
| Dividend Yield | 0.13% |
| Trailing Annual Div. Rate | 0.99 |
| Trailing Annual Div. Yield | 0.09% |
| Trailing EPS | 14.41 |
| Forward EPS | 32.14 |
| Book Value | 83.58 |
| Price-to-Book | 14.3 |
| Enterprise-to-Revenue | 25.41 |
| Enterprise-to-EBITDA | 73.35 |
| Ex-Dividend Date | 07/09/2026 |
| Earnings Date | |
| Earnings Call Date | |
| Earnings Average | 6.23 |
| Earnings Low | 5.99 |
| Earnings High | 6.5 |
| Revenue Average | 6.74B |
| Revenue Low | 6.28B |
| Revenue High | 6.97B |